David Kauffmann – Chairman
David Kauffmann has served as chairman of CMC, now CMC Biologics, since 2002. He is a founding general partner of EEP, a €80 million private equity fund investing in the life sciences and information technology/communication industries. At EEP, he focuses on investing in life science growth companies. Prior to EEP, David was principal at CAI, a New York-based private equity firm, where he also focused on investing in life science services companies. He served as chairman of Aster Cephac SA (now part of the SGS Group), a leading clinical research organization specializing in clinical trials and bioanalysis. He also was an investment manager of BioResearch Inc., a leading North American preclinical company acquired by Charles River Inc. He holds a Master of Business Administration from IMD in Lausanne, Switzerland.
Thomas Balland is an investment director at Innoven Partenaires, a Paris-based venture capital fund. He specializes in software, wireless, and medical devices investments. He has been a director of CMC Biologics since 2004 and also serves on the boards of Monte Cristo, Navx, SpineGuard, SpineVision and Traqueur (Alternext: ALTRA). Previously, Thomas was on the board of Innoven portfolio company gate5 AG, which was sold to Nokia in 2006. He was investment manager for Digiplug SA, sold to Faith (Tokyo: 4295), and has more than eight years of venture capital investment experience. Prior to joining Innoven in 2002, he held various positions with Mars Inc., Up&Up, and Vivendi. He has an Engineering degree from INSA Lyon and a Finance degree from ESCP-EAP.
Claes Glassell joined CMC Biologics as its chief executive officer in May 2011. He has been a member of CMC Biologics’ board of directors since 2005. Most recently, he was president and CEO of Cerus Corporation. He is the former president of Cambrex Corporation and previously held senior positions with Akzo Nobel, Nobel Industries, and Berol Kemi. His background includes more than 30 years of industry experience, including 20 years of executive leadership positions in publicly listed life science companies responsible for bioprocessing, active ingredients manufacture, registered therapeutic agents, and various support services. Claes has a Master of Science degree in Chemical Engineering from Chalmers University of Technology in Gothenburg, Sweden, and he attended the Advanced Management Program at Harvard Business School.
A director of CMC Biologics since 2005, Bill Henry is an investment partner at Celtic Pharma with particular responsibility for the manufacturing aspects of investments. Previously, he held a number of senior executive positions in biologics manufacturing including head of manufacturing at PowderMed (a successful DNA vaccine and device company that was acquired by Pfizer in 2006) and head of UCB Celltech Global Manufacturing. With a background in biochemistry, he joined Zeneca’s emerging bioproducts business to commission a large mycoprotein manufacturing capability before moving on to become the European operations director for the veterinary pharmaceutical business that was eventually acquired by Schering Plough. Bill began his career as a research scholar for British Petroleum and gained a Ph.D. in Chemistry from the University of Edinburgh.
Peter S. Laino
Peter S. Laino is a managing partner of Monitor Clipper Partners (MCP). He joined MCP in August 1998. Previously, he was director of development for K-III Communications Corporation, a media holding company formed by Kohlberg Kravis Roberts & Co., L.P. Earlier, he served as an associate in the corporate finance group of Dillon, Read & Co., Inc., and a principal of Riverside Partners, a small Monitor-sponsored private equity fund. He has also held a position as consultant at Monitor. Peter received a Bachelor of Arts degree, cum laude, in English from Williams College, and a Master of Business Administration from the Harvard Graduate School of Business Administration.
A founder of CMC Biologics, Mads Laustsen served as the CMC Biologics' CEO from 2001 until May 2011, when he was named to the board of directors. He currently serves as the company’s chief scientific officer responsible for technology and corporate development. Prior to establishing CMC Biologics, he worked for 16 years developing and manufacturing bulk enzymes and biopharmaceuticals at Novo, Zymogenetics, and Novozymes. Mads has served as a member of various advisory boards, has been active in development of new process technologies, and holds numerous patents in the field.
Steve Lehman, principal at Monitor Clipper Partners (MCP), joined CMC Biologics’ board of directors in 2008. Based out of MCP's Zurich office, Steve develops and manages growth equity and leveraged buyout investments throughout Europe. After several years working at Monitor Company Group (MCP’s strategy consulting affiliate), he joined MCP in 2003. He received a Bachelor of Arts degree, magna cum laude, in Economics and Mathematics from Williams College in Massachusetts. He also sits on the board of Microgame S.p.A., an Italy-based gaming technology company.
William L. Young
A founder and managing partner of Monitor Clipper Partners (MCP), William L. Young has worked with Monitor since 1989 and became a group managing director in 1995. Prior to joining Monitor, he was a founding partner of Westbourne Management Group in Toronto, Canada, providing management services to companies requiring or undertaking significant restructurings or turnarounds. From 1981 to 1989, William was a strategy consultant at Bain and Company in London, England, where he was elected to the partnership. He is a certified professional engineer and was previously employed as a design engineer by Imperial Oil, Exxon’s Canadian affiliate. William received a Bachelor’s degree with Honors from Queen’s University in Kingston, Ontario, and a Master of Business Administration with distinction from the Harvard Graduate School of Business Administration. He is currently on the board of Queen’s University in Kingston, Ontario, and the Belmont Day School, and he has served as director of Codere, Hinckley and Technal.